false 0001774857 0001774857 2025-11-05 2025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

## FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2025

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware | 001-42513 | 82-1606367
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050 |
San Diego, California |  | 92122
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.00001 per share |  | AARD |  | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

## Item 8.01 Other Events.

On November 5, 2025, Aardvark Therapeutics, Inc. (the “Company”) hosted an investor webinar to review its ARD-101 and ARD-201 programs, as well as its ObesityWeek 2025 presentations. A copy of the presentation used in connection with the webinar will be posted to the Company’s website and is also filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 8.01. The presentation is current as of November 5, 2025, and the Company disclaims any obligation to update this material in the future.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. |  | Description
99.1 |  | Presentation- ObesityWeek Investor Webinar, dated November 5, 2025.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document).

##

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | AARDVARK THERAPEUTICS, INC.
Date: | November 5, 2025 | By: | /s/ Tien-Li Lee, M.D.
|  |  | Tien-Li Lee, M.D. Chief Executive Officer